



February 13, 2026

The General Manager
Department of Corporate Services – CRD,
BSE Limited, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001.

Subject: Outcome of Board Meeting - Scrip Code:526139

Dear Sir/Madam,

This has reference to our letter dated January 28 2026.

- 1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company, for the Quarter ended 31.12.2025 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015.
- 2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter ended 31.12.2025 has also been approved.

The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For TRANSGENE BIOTEK LIMITED

**DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR**



M/S VASAVI & CO Chartered Accountants

Limited Review Report on Standalone unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To
The Board of Directors,
M/s TRANSGENE BIOTEK LIMITED
Hyderabad**

Limited Review Report on Standalone Unaudited Financial Results

We have reviewed the accompanying statement of unaudited Standalone Financial Results of M/s Transgene Biotek Limited (“the Company”) for the quarter and nine months ended December 31, 2025 (“the Statement”) being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time (“the Listing Regulations”).

This statement which is the responsibility of the Company’s Management and approved by the Board of Directors and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (“Ind AS 34 “Interim Financial Reporting”) prescribed under section 133 of the Companies Act 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



M/S VASAVI & CO Chartered Accountants

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For VASAVI & CO,
Chartered Accountants
FRN 020965S**

G.R.L. Vasavi

**(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259**



UDIN for this document is: 26249259RQQJKI3458

**Place: Hyderabad
Date: 13/02/2026**



M/S VASAVI & CO Chartered Accountants

Limited Review Report on Consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**To
The Board of Directors,
M/s Transgene Biotek Limited
Hyderabad**

Limited Review Report on Consolidated Unaudited Financial Results

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of M/s Transgene Biotek Limited (“the Parent”) and its Subsidiary (the Parent and its Subsidiary together referred to as “the Group”), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and 9 months ended December 31, 2025 (“the Statement”), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain



M/S VASAVI & CO Chartered Accountants

assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

2. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
3. The Statement includes the results of the following entities:
 1. Transgene Biotek HK Ltd - Subsidiary
4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June 2025, as considered in the consolidated unaudited financial results.

**For VASAVI & CO,
Chartered Accountants
FRN 020965S**

G.R.L. Vasavi



**(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259**

**UDIN for this document is: 26249259RQJJKI3458
Place: Hyderabad
Date: 13/02/2026**



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2025

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended	Year Ended
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	5.45	5.28	7.65	15.68	18.42	26.07
2	Other income (net)	0.00	0.00	4.38	0.00	73.96	78.35
3	Total income (1 + 2)	5.45	5.28	12.03	15.68	92.39	104.42
4	EXPENSES						
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.31	3.31	8.15	11.35	24.44	30.78
	Finance costs	27.35	26.43	1.73	78.33	5.18	24.30
	Depreciation and amortisation expense	4.98	4.98	2.32	14.93	6.97	9.32
	Other expenses	7.18	9.40	8.73	30.65	52.10	107.62
	Total expenses	42.82	44.12	20.93	135.26	88.68	172.03
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
8	Tax expense						
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
10	Other comprehensive income						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
12	Earnings per equity share						
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.05)	(0.05)	(0.01)	(0.16)	0.00	(0.09)
	Diluted (Rs.)	(0.05)	(0.05)	(0.01)	(0.16)	0.00	(0.09)

Notes:

- The matter in SAT has not progressed much further to report after the last Board meeting and the next date of hearing is scheduled for 24th February 2026.
- Hearing at the Appellate Tribunal, New Delhi continues to be in progress and the next date of hearing posted for 14th April 2026.
- The appeal at NCLT Hyderabad bench has not yet come for hearing and next date is set for 3rd March 2026.
- No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0
- The auditors have carried out a limited review of the financial results for the quarter ended 31st December 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 13th February 2026.

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 13/02/2026
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements

Other expenses (In Lakhs)

Particulars	For the Period ended on 31st December 2025
Advertisement	0.22
BSNL Fiber net	0.02
Contractual expenses	0.27
Conveyance Expenses	0.06
Directors sitting fee	0.15
E Voting charges	0.07
Legal and Professional Charges	3.24
Office Expenses	0.20
Postage and Courier Expenses	0.00
Rates, taxes and duties	0.02
PCB renewal	2.87
Telephone Expenses	0.02
Website and Software	0.04
Total	7.18

For TRANSGENE BIOTEK LIMITED

**Dr.K.Koteswara Rao**
Managing Director**Date: 13/02/2026****Place:Hyderabad**



TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2025

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures Previous year ended	Year Ended
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from operations	5.45	5.28	7.65	15.68	18.42	26.07
2	Other income (net)	0.00	0.00	4.38	0.00	73.96	78.35
3	Total income (1 + 2)	5.45	5.28	12.03	15.68	92.39	104.42
4	EXPENSES						
	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	3.31	3.31	8.15	11.35	24.44	30.78
	Finance costs	27.35	26.43	1.73	78.33	5.18	24.30
	Depreciation and amortisation expense	4.98	4.98	2.32	14.93	6.97	9.32
	Other expenses	7.18	9.40	8.73	30.65	52.10	107.62
	Total expenses	42.82	44.12	20.93	135.26	88.68	172.03
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
8	Tax expense						
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
10	Other comprehensive income						
	A Items that will not be reclassified subsequently to profit or loss						
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	-37.38	-38.84	-8.90	-119.59	3.70	-67.61
12	Earnings per equity share						
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	(0.05)	(0.05)	(0.01)	(0.16)	0.00	(0.09)
	Diluted (Rs.)	(0.05)	(0.05)	(0.01)	(0.16)	0.00	(0.09)

Notes:

- The matter in SAT has not progressed much further to report after the last Board meeting and the next date of hearing is scheduled for 24th February 2026.
- Hearing at the Appellate Tribunal, New Delhi continues to be in progress and the next date of hearing posted for 14th April 2026.
- The appeal at NCLT Hyderabad bench has not yet come for hearing and next date is set for 3rd March 2026.
- No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0
- The auditors have carried out a limited review of the financial results for the quarter ended 31st December 2026 and following the approval by the audit committee, it has been passed by the Board of Directors at the meeting held on 13th February 2026.

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

Date: 13/02/2026
Place:Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Consolidated financial statements****Other expenses (In Lakhs)**

Particulars	For the Period ended on 31st December 2025
Advertisement	0.22
BSNL Fiber net	0.02
Contractual expenses	0.27
Conveyance Expenses	0.06
Directors sitting fee	0.15
E Voting charges	0.07
Legal and Professional Charges	3.24
Office Expenses	0.20
Postage and Courier Expenses	0.00
Rates, taxes and duties	0.02
PCB renewal	2.87
Telephone Expenses	0.02
Website and Software	0.04
Total	7.18

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao
Managing Director****Date: 13/02/2026****Place:Hyderabad**